Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935953 | 1.00 | LMNA (0.40) | LMNATSHRANPEPALDH1A1TDP1 | |
| SCHEMBL21691058 | 0.90 | ALDH1A1 (0.36) | LMNATSHRANPEPALDH1A1TDP1 | |
| SCHEMBL12575017 | 0.86 | ANPEP (0.44) | TSHRANPEPTDP1ADH1BADH1C | |
| SCHEMBL2232621 | 0.86 | LMNA (0.53) | LMNAALDH1A1TDP1KDM4ETHRB | |
| SCHEMBL15540151 | 0.84 | TDP1 (0.45) | LMNATSHRALDH1A1TDP1KDM4E | |
| Propylene Glycol SCHEMBL17512354 | 0.83 | TDP1 (0.59) | LMNATSHRANPEPALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL7626501 | 0.83 | LMNA (0.50) | LMNAALDH1A1TDP1KDM4ETHRB | |
| SCHEMBL3754712 | 0.83 | LMNA (0.50) | LMNAALDH1A1TDP1KDM4ETHRB | |
| SCHEMBL11231989 | 0.80 | LMNA (0.36) | LMNATSHRANPEPALDH1A1TDP1 | |
| SCHEMBL7054364 | 0.79 | ANPEP (0.40) | TSHRANPEPALDH1A1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2020185999-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20060258652-A1 | Beta-blockers having antioxidant and no-donor activity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-11-16 | — | — | US | disclosed |
| WO-2004047837-A2 | BETA-BLOCKERS HAVING ANTIOXIDANT AND NITRIC OXIDE-DONOR ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | LMNA 637/4885TSHR 2876/4885ANPEP 12/4885 |
| US-20060258652-A1 | Beta-blockers having antioxidant and no-donor activity | ADRB1, ADRB2, ADRB3 | LMNA 1973/4885TSHR 1133/4885ANPEP 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.